US Pharma R&D spending hits $100 billion, driving digitization and relocation

💊 The Top 10 Pharmaceutical Companies in the USA in 2025 From Pfizer to Sanofi, these pharma giants are driving innovation across clinical research, biotechnology, and patient care. But to connect with their key decision-makers, precision data is non-negotiable. That’s where MedicoLeads, a trusted B2B healthcare database provider, empowers marketers and agencies with verified, compliant, and high-performing pharma contacts. Plan smarter outreach, personalize engagement, and boost campaign ROI with accurate healthcare intelligence. 👉 Explore full insights: https://lnkd.in/diwD6xjx #healthcaremarketing #pharmaindustry #b2bhealthcare #pharmaceuticalmarketing #healthcaredata #medicoleads #b2bdatabase #marketingintelligence

Our region’s economy is evolving and the healthcare and biopharma sectors are playing a leading role. Governor Glenn Youngkin announced a new partnership between the VIPC | Virginia Innovation Partnership Corporation and AstraZeneca, Eli Lilly and Company and Merck. Together they will invest $120 million to establish the Virginia Center for Advanced Pharmaceutical Manufacturing (VCAPM), expanding job training and creating new, high-quality opportunities in a crucial and fast-growing industry. This initiative will open thousands of pathways in advanced manufacturing and pharmaceutical production, helping diversify the regional economy and strengthen the pipeline of skilled talent ready to meet global demand. For businesses, it’s another step toward a more resilient, innovative and competitive region. Learn more about the VCAPM project at CBS19 News (via Mark Gad): https://bit.ly/4oVkxoq 

The numbers say it all: 94% of pharma leaders are either running, launching, or planning direct-to-patient (DTP) programs. As Nicholas Jacobus reported for Pharmaceutical Executive, DTP has officially moved from pilot to practice, and the focus is clear: reducing friction, accelerating care, and building trust. As ixlayer’s Matthew Walsh shared: “The common thread is direct-to-patient solutions that feel simple and seamless for the patient, connect back to their doctor (or help them find one) and make pharma marketing initiatives more actionable.” Read our summary of the coverage here: https://lnkd.in/eTTH62-3 #DigitalHealth #Pharma #PatientAccess #DTP #ixlayer

We at POMS have been tracking several major developments in pharmaceutical manufacturing, and the scale of investment is remarkable. These announcements are centered in the nation’s top manufacturing hubs and signal a new phase of growth across the United States. 🔹 Novartis is investing $23 billion dollars in U.S. manufacturing and R&D, including expansion across the Greater Boston biotech corridor. https://lnkd.in/eCh5ib_a 🔹 Eli Lilly has committed $27 billion dollars for new facilities across the Midwest and Indiana, now rising as high growth biopharma hubs. https://lnkd.in/emikGbiq 🔹 Roche has announced $50 billion dollars in pharmaceutical and diagnostics investment, with major activity in California, including the Bay Area and Southern California.https://https://lnkd.in/ez5BzTqJ. Together they reflect a broader wave of facility expansion and digital modernization that will shape how therapies are produced in the years ahead. For more than 38 years, POMS has supported teams in hubs such as Boston, the Bay Area, San Diego, and North Carolina as they launch digital first, compliant, and scalable operations. Are your MES and data systems built to handle multi-site expansion? If you are beginning to evaluate what a more flexible and future ready MES should look like, we would be glad to show how POMS is supporting multi-site growth and advanced digital capabilities. Learn more at www.poms.com or contact us at sales@poms.com #PharmaMES #Biomanufacturing #DigitalManufacturing #LifeSciences #ManufacturingInnovation #POMS

Meet OneUK partner, Catalent. Catalent, a global leader in contract development and manufacturing, plays a vital role in Kentucky’s economy and the healthcare industry worldwide. With its facility in Winchester, Catalent specializes in helping pharmaceutical and biotech companies bring life-changing medicines to patients faster and more efficiently. Now, through the University of Kentucky’s OneUK initiative, Catalent is deepening its engagement with UK to strengthen the state’s workforce, advance innovation and create lasting economic impact. Read more about Catalent and how the OneUK partnership is advancing Kentucky: https://lnkd.in/eGHZYsGA

The Challenge of Global Pharma Launches Innovation is the lifeblood of the pharmaceutical industry — yet transforming a scientific breakthrough into a medicine that truly reaches patients remains one of our greatest challenges. In my recent article for "Marketing Farmacêutico", I try to explore the complexity behind global launches: from building truly cross-functional teams to balancing global consistency with local market realities, and from proving efficacy to demonstrating real-world value. As the industry evolves traditional business models are no longer enough. Success now depends on collaboration, data-driven decisions, and innovative access strategies that align value creation with healthcare system sustainability. If you want to learn more, please join us on the Global Pharma 4 (https://lnkd.in/dkMcWPgq) so we can reflect together on how we can rethink global launches to better serve both patients and healthcare systems. Please find the full article here: https://lnkd.in/dem-hSg6. #Pharma #GlobalLaunch #HealthcareInnovation #MarketAccess #CustomerExperience #GlobalPharma4 CC Daniel Guedelha; João Santos Pereira; Nina Fernandes, MD

**Analyzing Strategic Adjustments in Pharma Investments** Recent data indicates that Virtus Family Office LLC decreased its holdings in Pfizer Inc. by 35.5%, now owning 52,394 shares. This prompts a question: What factors are driving such strategic adjustments in pharmaceutical investments within Family Offices? At Regarde Familia Family Office, we continuously assess market dynamics and evolving healthcare trends to refine our investment strategies. Understanding the rationale behind similar decisions can offer valuable insights into our own portfolios. What adjustments are you making in your investments as market conditions shift? #investing #innovation #familyoffice #finance

I rarely comment outside of liver science but, as somebody who has worked all over the world from the ward to the computing labs, I've been fortunate enough to see, first hand, how culture and politics influence science. Which is why when EMJ asked me to comment on the UK's drop in investment attractiveness to pharma, I thought I'd jump in. Let's be clear. There certainly is room for debate around proximal issues like post-Brexit UK's global positioning, how much drugs should cost, and if pharma investment universally translates into improved population health. However my view remains that what we're witnessing are cracks appearing after decades of UK neglect to prioritise the industrialisation of drug R&D at a level that the US and China have been. In the UK, we're too proud of our universities and basic science, and not proud enough of what it takes to impact patient lives.

CareSet's latest blog "10 Essential Strategies for Effective Commercial Operations Management" reveals how pharmaceutical companies can optimize their operations through data-driven approaches. Key takeaways for life sciences leaders: - Leverage Medicare data insights to uncover treatment patterns and provider influence, improving strategic decision-making - Implement Lean and Six Sigma methodologies to streamline processes - 77.98% of such initiatives lead to measurable operational improvements - Establish clear KPIs aligned with strategic objectives to enhance performance monitoring - Develop robust compliance programs to navigate legal complexities in the pharmaceutical landscape - Utilize comprehensive financial oversight to maintain stability - critical as 82% of firms fail due to cash flow problems These actionable strategies help pharmaceutical companies navigate market complexities while improving patient outcomes and operational efficiency. https://lnkd.in/d2hjeW57 #PharmaceuticalStrategy #CommercialOperations #MedicareData #HealthcareAnalytics #OperationalEfficiency

Pharma Research 2025 — now available!   The Pharma Research 2025 report unveils the structural shifts shaping Europe’s, Iberia’s, and Portugal’s pharmaceutical sector: •       Evolving patterns in global medicine use and therapeutic demand; •       Growing M&A activity and strategic repositioning among leading pharmaceutical groups across Europe and Iberia; •       The influence of interest rates and capital market dynamics on valuations, financing, and deal execution in the pharma industry; •       A focused analysis of Portugal’s market performance, competitive structure, and innovation trajectory; •       Forward-looking insights on the strategic imperatives driving the next cycle of growth and transformation in the European and Iberian pharmaceutical landscape.   Reach out for the complete version at geral@glowsidegroup.com.   #PharmaResearch2025 #Glowside #HealthcareStrategy #PharmaInsights #MergersAndAcquisitions #CorporateFinance